HLA-C rs926404: What Your Genotype Means

What each genotype means

Genomic Location and the Nature of rs926404

The single nucleotide polymorphism rs926404 resides in the major histocompatibility complex (MHC) class I region on the short arm of human chromosome 6 (6p21.33). Specifically, it maps roughly 35 kilobases upstream from the transcription start site of the human leukocyte antigen C (HLA-C) gene, earning it the common designation of the '-35' HLA-C variant in early literature. In genomic catalogs, rs926404 commonly reflects a nucleotide transition involving cytosine (C) and thymine (T) alleles. Because the human leukocyte antigen region features exceptionally high linkage disequilibrium—meaning large swaths of adjacent genetic variants are inherited together as uninterrupted blocks—rs926404 acts as an informative genetic marker or tagging SNP. While it is strongly correlated with downstream gene activity, modern molecular research demonstrates that rs926404 is largely an indirect proxy for complex haplotype structures and regulatory elements rather than a singular causative disruption to the HLA-C coding sequence.

Biological Function of the HLA-C Gene

The HLA-C gene encodes a classical human leukocyte antigen class I heavy chain that pairs with beta-2 microglobulin to form functional cell-surface heterodimers. Unlike other class I molecules such as HLA-A and HLA-B, HLA-C typically exhibits lower baseline cell surface expression but plays a specialized dual role in human immunity. First, HLA-C presents intracellular peptide antigens—including viral fragments—to CD8+ cytotoxic T lymphocytes, directing the targeted destruction of compromised cells. Second, HLA-C serves as a major physiological ligand for killer-cell immunoglobulin-like receptors (KIRs) expressed on natural killer (NK) cells. Through these interactions, HLA-C molecules fine-tune innate immune surveillance and regulate NK cell inhibition or activation. Importantly, during HIV-1 infection, the viral protein Nef actively downregulates surface HLA-A and HLA-B molecules to evade T-cell detection, but HLA-C is relatively resistant to Nef-mediated removal, placing an outsized responsibility on HLA-C for antiviral vigilance.

Research Findings on HIV-1 Viral Control and Immune Traits

Genome-wide association studies evaluating natural host control of HIV-1 identified upstream HLA-C markers, notably tagging variants like rs926404, as significant statistical determinants of steady-state plasma viral loads. Individuals carrying the -35C-associated alleles frequently demonstrate higher baseline HLA-C mRNA and cell surface expression levels. In observational cohorts, this elevated surface density has been correlated with lower plasma viral loads, reduced rates of viral replication, and slower untreated progression toward advanced infection. Researchers hypothesize that elevated HLA-C expression enhances viral peptide presentation to cytotoxic T cells and improves natural killer cell licensing. However, this immunological boost can carry trade-offs. While higher HLA-C expression appears protective against chronic viral progression, elevated baseline levels have also been correlated with an increased susceptibility to inflammatory conditions such as Crohn's disease, highlighting a delicate evolutionary balance between pathogen defense and autoimmune pathology.

Evaluating Evidence Strength and Scientific Uncertainty

The evidence catalog categorizes rs926404's clinical directness as limited, largely due to biological complexity and fine-mapping challenges. While the statistical link between rs926404 and HLA-C expression levels has been replicated across multiple European and African American cohorts, rs926404 is not universally accepted as the sole functional variant. Subsequent studies have identified other functional motifs in tight linkage disequilibrium, such as 3' untranslated region microRNA binding site variations (e.g., rs67384697 altering miR-148a binding) and distinct structural HLA-C allotypes that independently dictate cell-surface trimer stability. Furthermore, in certain ancestries, extended haplotypes can alter these relationships, making rs926404 a less consistent surrogate outside specific demographic populations. Because HLA-C expression is driven by multidimensional genetic and post-transcriptional regulators, relying strictly on rs926404 offers only an incomplete view of an individual's immunological profile.

Practical Implications: What This Means for Consumers

Discovering your rs926404 genotype through consumer genetic testing provides educational insight into immune regulation research, but it does not carry direct medical utility. Having a genotype linked to higher HLA-C expression does not provide immunity against acquiring HIV-1 or other pathogens, nor does it guarantee protection against disease progression. Conversely, possessing alleles associated with lower expression is not a diagnosis of immune deficiency. Direct-to-consumer genotyping cannot replace standard medical screening, preventive practices, or clinician-directed monitoring. Furthermore, rs926404 must not be used to predict disease onset or guide personal healthcare decisions. Anyone with concerns about viral exposure, ongoing infectious diseases, or autoimmune symptoms should speak directly with a licensed healthcare professional rather than interpreting raw genetic data independently.

Frequently asked questions

Sources & further reading